Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Phase 1/2 Completed 8 enrolled Johns Hopkins University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration

Timeline

Start: 2003-05
Primary completion: 2005-06
Completion: 2005-06

Publications

Ibrahim MA, Do DV, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. BMC Pharmacol Toxicol. 2013 Jan 14;14:7. doi: 10.1186/2050-6511-14-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	fosbretabulin	Small molecule	27 mg/m2	Intravenous
Subject	fosbretabulin	Small molecule	36 mg/m2	Intravenous
Subject	fosbretabulin	Small molecule	45 mg/m2	Intravenous

Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration

Summary

Timeline

Publications

Drugs

Indications